MX2018008469A - Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. - Google Patents

Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Info

Publication number
MX2018008469A
MX2018008469A MX2018008469A MX2018008469A MX2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A MX 2018008469 A MX2018008469 A MX 2018008469A
Authority
MX
Mexico
Prior art keywords
devices
end portion
methods
medicament container
disorderswith
Prior art date
Application number
MX2018008469A
Other languages
English (en)
Inventor
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of MX2018008469A publication Critical patent/MX2018008469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos y dispositivos para tratar la AMD húmeda, CNV, AMD húmeda asociada con CNV y/o AMD húmeda asociada con RVO en un sujeto humano que lo necesite. En ciertos aspectos, los dispositivos que sé proporcionan en la presente incluyen un recipiente de medicamento que define un lumen configurado para contener un medicamento, una porción del extremo distante del recipiente de medicamento que incluye una porción de acoplamiento configurada para acoplarse de manera desmontable a un conjunto de aguja, una porción del extremo próximo del recipiente de medicamento que incluye una pestaña y un hombro longitudinal; un conjunto de pistón que incluye una porción del extremo distante dispuesta de manera móvil dentro del lumen del recipiente de medicamento; y un asa acoplada a una porción del extremo próximo del conjunto de pistón.
MX2018008469A 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos. MX2018008469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US201662324708P 2016-04-19 2016-04-19
PCT/US2017/012757 WO2017120601A1 (en) 2016-01-08 2017-01-09 Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics

Publications (1)

Publication Number Publication Date
MX2018008469A true MX2018008469A (es) 2018-11-09

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008469A MX2018008469A (es) 2016-01-08 2017-01-09 Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.

Country Status (9)

Country Link
EP (1) EP3400014A1 (es)
JP (1) JP2019501200A (es)
KR (1) KR20180101488A (es)
CN (1) CN108778330A (es)
AU (1) AU2017206114A1 (es)
BR (1) BR112018013805A2 (es)
CA (1) CA3010862A1 (es)
MX (1) MX2018008469A (es)
WO (1) WO2017120601A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
AU2014259694B2 (en) 2013-05-03 2018-11-08 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
EP3496680A1 (en) 2016-08-12 2019-06-19 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
AU2018342094A1 (en) * 2017-09-27 2020-04-02 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab
SG11202005719UA (en) * 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
EP3946467A1 (en) * 2019-04-03 2022-02-09 REGENXBIO Inc. Gene therapy for eye pathologies
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020383580A1 (en) * 2019-11-11 2022-05-12 Cstone Pharmaceuticals Pharmaceutical combination and use thereof
EP4106755A4 (en) * 2020-02-19 2024-03-27 Clearside Biomedical Inc COMPOSITIONS CONTAINING AXITINIB AND METHODS FOR TREATING OCULAR DISEASES
EP4164593A1 (en) * 2020-06-15 2023-04-19 OPKO Pharmaceuticals, LLC Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
TW202313095A (zh) * 2021-05-17 2023-04-01 美商再生元醫藥公司 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714734A1 (en) * 2011-05-27 2014-04-09 Novartis AG Method of treating vision disorders
WO2013126799A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
MX2015005839A (es) * 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
US20160310417A1 (en) * 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
CA2952822A1 (en) * 2014-06-17 2015-12-23 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders

Also Published As

Publication number Publication date
EP3400014A1 (en) 2018-11-14
CA3010862A1 (en) 2017-07-13
WO2017120601A1 (en) 2017-07-13
BR112018013805A2 (pt) 2018-12-11
KR20180101488A (ko) 2018-09-12
AU2017206114A1 (en) 2018-08-02
JP2019501200A (ja) 2019-01-17
CN108778330A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
MX2018008469A (es) Metodos y dispositivos para tratar trastornos oculares posteriores con aflibercept y otros productos biologicos.
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
PH12014502792A1 (en) Soft tip cannula
MX2017000920A (es) Dispositivos magneticos para anastomosis y metodos de entrega.
MX2016016070A (es) Introductor y guia de cateter con aguja tangencial subretinal.
EP2456363A4 (en) INTRODUCTION INSTRUMENT FOR PROSTHETIC VALVE
MX2020008980A (es) Dispositivo de administracion de farmacos.
EP4324414A3 (en) Devices and methods for treating the skin using a rollerball or a wicking member
WO2015164839A3 (en) System and method for safety syringe
MX2018012770A (es) Funda para sonda de oximetria portatil.
IN2015DN02530A (es)
WO2014127389A3 (en) Thrombectomy catheter
NZ630742A (en) A patient interface
MX2019010386A (es) Jeringa de clip.
GB201318950D0 (en) Deployment Catheter
MX2017000609A (es) Dispositivo y metodo de entrega de implante ocular.
Siqueira et al. Improvement of ischaemic macular oedema after intravitreal injection of autologous bone marrow-derived haematopoietic stem cells.
MX2017001673A (es) Prenda de compresion medica terapeutica y metodo.
MX2020011003A (es) Valvula para dilatador y ensamble de cubierta.
MX2016004859A (es) Conector de cateter.
MY192494A (en) Vaginal composition and use thereof
EA033212B1 (ru) Ланцетное устройство для лечения дерматологических расстройств и способ его применения
WO2017079325A3 (en) Injection devices and systems and methods for using them
MX2017001555A (es) Dispositivo para insertar una canula de punta roma bajo la piel de un paciente.
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.